Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) develops authoritative, independent and evidence-based recommendations for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE develops technology appraisal guidance for the NHS on all new cancer drugs, including for neuroblastoma, and NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.
NICE is currently appraising the drug dinutuximab beta for use in the treatment of high-risk neuroblastoma and has not yet issued final guidance. NICE recently consulted on its draft recommendations and will take the comments it received fully into account in developing its final guidance.
NICE has also been asked to appraise the drug dinutuximab for use in the treatment of high-risk neuroblastoma but the manufacturer asked for the drug’s marketing authorisation to be withdrawn because of supply issues and NICE’s appraisal has now been suspended.